MiMedx Group (MDXG) and Nevro (NYSE:NVRO) Head-To-Head Comparison

MiMedx Group (NASDAQ: MDXG) and Nevro (NYSE:NVRO) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.


This table compares MiMedx Group and Nevro’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
MiMedx Group 11.64% 17.49% 12.69%
Nevro -14.09% -17.27% -9.88%

Analyst Ratings

This is a breakdown of current recommendations for MiMedx Group and Nevro, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MiMedx Group 1 0 3 0 2.50
Nevro 0 1 6 0 2.86

MiMedx Group presently has a consensus price target of $17.00, suggesting a potential upside of 40.03%. Nevro has a consensus price target of $99.71, suggesting a potential upside of 41.44%. Given Nevro’s stronger consensus rating and higher possible upside, analysts plainly believe Nevro is more favorable than MiMedx Group.

Valuation and Earnings

This table compares MiMedx Group and Nevro’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MiMedx Group $245.01 million 5.50 $11.97 million $0.30 40.47
Nevro $228.50 million 9.14 -$31.77 million ($1.45) -48.62

MiMedx Group has higher revenue and earnings than Nevro. Nevro is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

MiMedx Group has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, Nevro has a beta of -0.83, indicating that its stock price is 183% less volatile than the S&P 500.

Institutional and Insider Ownership

69.4% of MiMedx Group shares are owned by institutional investors. 12.4% of MiMedx Group shares are owned by insiders. Comparatively, 12.1% of Nevro shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.


MiMedx Group beats Nevro on 9 of the 13 factors compared between the two stocks.

MiMedx Group Company Profile

MiMedx Group, Inc. is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company’s Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. Its biomaterial platform technologies include AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. OrthoFlo is amniotic fluid-derived allograft for homologous use. Physio is a bone grafting material consists of bone tissue with no added carrier. CollaFix, its new brand, is its collagen fiber technology designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair.

Nevro Company Profile

Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. Its HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain. HF10 therapy enables patients to achieve sustained pain relief without paresthesia, thus enabling its patients to avoid the uncomfortable shocking or jolting sensations commonly associated with paresthesia. HF10 therapy relies on consistent anatomical lead placement. As of December 31, 2016, it was investigating the use of HF10 therapy to address additional indications, such as chronic upper limb and neck pain, painful neuropathies and non-surgical refractory back pain. The Senza system is approved to create electrical impulses from 2 hertz (Hz) to 10,000 Hz.

Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply